Table 4.
Odds ratio and 95% confdence interval for coronary collateral growth
| Models | MetS | MetS after GEE | ||
|---|---|---|---|---|
| OR (95%CI) | P Value | OR (95%CI) | P Value | |
| Model 1 | 1.690 (1.326–2.155) | < 0.001 | 1.690 (1.328–2.152) | < 0.001 |
| Model 2 | 1.695 (1.328–2.162) | < 0.001 | 1.695 (1.331–2.158) | < 0.001 |
| Model 3 | 1.709 (1.338–2.183) | < 0.001 | 1.709 (1.340–2.179) | < 0.001 |
| Model 4 | 1.765 (1.337–2.331) | < 0.001 | 1.765 (1.335–2.333) | < 0.001 |
| Model 5 | 1.721 (1.273–2.325) | 0.001 | 1.721 (1.276–2.320) | < 0.001 |
| Model 6 | 1.882 (1.185–2.989) | 0.007 | 1.862 (1.093–3.172) | 0.022 |
| Model 7 | 1.892 (1.096–3.268) | 0.022 | 1.892 (1.107–3.236) | 0.020 |
| Model 8 | 1.921 (1.109–3.326) | 0.020 | 1.921 (1.120–3.292) | 0.018 |
Model 1: adjusted for age, sex
Model 2: adjusted for age, sex, heart rate, renal disease, former smoker, current smoker
Model 3: adjusted for age, sex, heart rate, renal disease, former smoker, current smoker, prior myocardial infarction, stroke, history of percutaneous coronary intervention
Model 4: adjusted for age, sex, heart rate, renal disease, former smoker, current smoker, prior myocardial infarction, stroke, history of percutaneous coronary intervention, white blood cell, homocysteine, platelet, creatinine, eGFR, glycated albumin, uric acid
Model 5: adjusted for age, sex, heart rate, renal disease, former smoker, current smoker, prior myocardial infarction, stroke, history of percutaneous coronary intervention, white blood cell, homocysteine, platelet, creatinine, eGFR, glycated albumin, uric acid,ventricular ejection fraction; left ventricular end-diastolic dimension; left ventricular end-systolic dimension;
Model 6: adjusted for elevated body mass index, elevated blood pressure, elevated fasting glucose, reduced high-density lipoprotein cholesterol,elevated triglycerides;
Model 7: adjusted for age, sex, heart rate, renal disease, former smoker, current smoker, prior myocardial infarction, stroke, history of percutaneous coronary intervention, white blood cell, homocysteine, platelet, creatinine, eGFR, glycated albumin, uric acid, ventricular ejection fraction; left ventricular end-diastolic dimension; left ventricular end-systolic dimension elevated,body mass index, elevated blood pressure, elevated fasting glucose, reduced high-density lipoprotein cholesterol, elevated triglycerides
Model 8: adjusted for age, sex, heart rate, renal disease, former smoker, current smoker, prior myocardial infarction, stroke, history of percutaneous coronary intervention, white blood cell, homocysteine, platelet, creatinine, eGFR, glycated albumin, uric acid, ventricular ejection fraction; left ventricular end-diastolic dimension; left ventricular end-systolic dimension elevated, body mass index, elevated blood pressure, elevated fasting glucose, reduced high-density lipoprotein cholesterol, elevated triglycerides, Diuretics, ACE inhibitors/ARBs, β-blockers, CCBs, hypoglycaemic agents
GEE generalized estimating equation, OR odd ratio, MetS metabolic syndrome